Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric, Open-label, Non-randomized Study to Evaluate the Pharmacokinetic, Safety and Tolerability of ITF2357 Given as an Oral Single 50 mg Dose in Participants With Chronic Hepatic Impairment Relative to Matched Participants With Normal Hepatic Function

NCT06736223 is registered in ClinicalTrials.gov with Italfarmaco as lead sponsor.

NCT NCT06736223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06736223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric, Open-label, Non-randomized Study to Evaluate the Pharmacokinetic, Safety and Tolerability of ITF2357 Given as an Oral Single 50 mg Dose in Participants With Chronic Hepatic Impairment Relative to Matched Participants With Normal Hepatic Function
Lead sponsor
Italfarmaco
Phase
Phase 1
Overall status
Completed
Start date
May 29, 2025
Completion date
August 14, 2025
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment